Diabetes, obesity & metabolism · 2026
Comparison of Diluted Insulin (U10) Versus Standard (U100) Insulin in Automated Insulin Delivery Systems: Reducing Time Below Range in Young Children.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Falk Heidi, Aaltio Ada, Pulkkinen Mari-Anne, Varimo Tero, Tuomaala Anna-Kaisa
Аннотация
BACKGROUND: Treating young children with Type 1 diabetes (CwT1D) is challenging due to their very small need for insulin. We investigated the safety of diluted insulin (U10) in the AID system and how its use affected glycaemic outcomes compared to standard insulin.
METHODS: Patients aged 0-4 years who initiated treatment with diluted insulin in an AID system during the years 2020-2025 were identified from the diabetes registry (N = 19). They had a maximum daily insulin dose of ≤ 6 units. An age and gender-matched control group (N = 27) using standard insulin (U100) in an AID system was determined. Longitudinal CGM outcomes were analysed within the treatment group from the start of diluted insulin and between groups from diagnosis over 12 months to assess time-by-treatment effects.
RESULTS: After 3 months of diluted insulin use, TBR < 3.9 and TBR < 3.0 decreased significantly (from 4.6% ± 4.1% to 2.7% ± 2.5%, p = 0.008; from 1.2% ± 1.8% to 0.4% ± 0.6%, p = 0.01, respectively) and remained low through 12 months. Compared with controls, children using diluted insulin had lower TBR < 3.9 mmol/L at later follow-up visits. In the HbA1c-adjusted mixed-effects model, the between-group difference in change from 3 months was -1.85 percentage points at 9 months (95% CI: -3.26 to -0.44, p = 0.010) and -1.52 percentage points at 12 months (95% CI: -2.92 to -0.13, p = 0.032). No significant between-group changes in other CGM measures over time were observed.
CONCLUSION: The use of diluted insulin in young CwT1D, who require low insulin doses and use an automated insulin delivery system, reduces time below range with no evidence of increased hyperglycaemia.
METHODS: Patients aged 0-4 years who initiated treatment with diluted insulin in an AID system during the years 2020-2025 were identified from the diabetes registry (N = 19). They had a maximum daily insulin dose of ≤ 6 units. An age and gender-matched control group (N = 27) using standard insulin (U100) in an AID system was determined. Longitudinal CGM outcomes were analysed within the treatment group from the start of diluted insulin and between groups from diagnosis over 12 months to assess time-by-treatment effects.
RESULTS: After 3 months of diluted insulin use, TBR < 3.9 and TBR < 3.0 decreased significantly (from 4.6% ± 4.1% to 2.7% ± 2.5%, p = 0.008; from 1.2% ± 1.8% to 0.4% ± 0.6%, p = 0.01, respectively) and remained low through 12 months. Compared with controls, children using diluted insulin had lower TBR < 3.9 mmol/L at later follow-up visits. In the HbA1c-adjusted mixed-effects model, the between-group difference in change from 3 months was -1.85 percentage points at 9 months (95% CI: -3.26 to -0.44, p = 0.010) and -1.52 percentage points at 12 months (95% CI: -2.92 to -0.13, p = 0.032). No significant between-group changes in other CGM measures over time were observed.
CONCLUSION: The use of diluted insulin in young CwT1D, who require low insulin doses and use an automated insulin delivery system, reduces time below range with no evidence of increased hyperglycaemia.